ASSESSING THE INITIAL REACTION OF ADULT PARTICIPANTS SUFFERING FROM SERIOUS DEPRESSION TO ANTIDEPRESSANT DRUGS

Abstract

Background: It has been demonstrated that evaluating the early response to antidepressant medication after two to four 
weeks may reliably predict remission by eight to twelve weeks. Most of the earlier literature's data assessed randomised 
controlled trials.  
Aim: The purpose of the current study was to assess how adult participants with severe depressive disorder responded to 
antidepressant drugs early on.  
Methods: At different time periods, the study evaluated different baseline reductions in Patient Health Questionnaire 9 
scores. Clinical and demographic information from both early responders and patients who did not receive an early 
response was evaluated. Additionally, in week 14, it was evaluated if an early reaction was indicative of a response, 
remission, and more than a little improvement.  
Results: The logistic regression models were significant with a p-value of less than 0.001 and had a high accuracy of 
78.2% in predicting remission. Compared to non-early responders, early responders had 3.2 times higher likelihood of 
remission. Similar findings were seen for the answer, with an accuracy of 66.3% and a significance level of p<0.001. 
Comparable outcomes for the GTMI were seen, demonstrating a high degree of significance with p<0.001 and an accuracy 
of 74.4%. At 14 weeks, the early response group showed 3.6 times the high response, whereas the non-early responders' 
GTMI was 4.9 times greater. 
Conclusion: The current study finds that early response is associated with improved treatment results at week 14. 
Dopamine reuptake inhibitors and norepinephrine were administered to participants who did not respond by week 4 in the 
hopes that these subjects would have better outcomes.